Today: March 30, 2017, 12:50 am

Just Published: "U.S. Insomnia Market - Forecasts to 2021"

New Medical Devices research report from Markets and Markets is now available from Fast Market Research
Just Published: "U.S. Insomnia Market - Forecasts to 2021" 2017-02-17 15:55:22
U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon), Orexin Antagonist) & OTC Treatment (Antihistamine, Melatonin, Valerian Root)) - Forecasts to 2021

The U.S. insomnia market is projected to reach USD 4.24 billion by 2021 from USD 3.38 billion in 2016, growing at a CAGR of 4.6% from 2016 to 2021.

In 2016, the cognitive behavioural therapy for insomnia (CBTI) segment is expected to account for the largest share of the market. The other alternative therapies include exercise/yoga, acupuncture, biofeedback, bright light therapy, music therapy, and aroma therapy.

Full Report Details at
- ..

In 2016, the prescription sleep aids segment is expected to account for the largest share of the U.S. insomnia pharmacological treatment market. The launch of Belsomra (Merck & Co., Inc) in 2014 in the U.S. and the anticipated launch of E-2006 (Eisai Co., Ltd.) is expected to drive the growth of the market during the forecast years. However, due to the erosion in branded drugs sales and growing adoption of generics attributed to their low cost and equal efficacy as compared to branded products may hinder the growth of the market. In 2016, the zolpidem segment is expected to account for the largest share of the non-benzodaizepines prescription sleep aids market. However, higher adoption of generic products that are available are cheaper price is negatively affecting the growth of the market.

The over-the-counter sleep aids segment of the U.S. insomnia pharmacological treatment market is expected to grow at the highest CAGR during the forecast period. Reasons attributing to the growth of this market include easier availability, low prices, and publicity regarding the side effects of the prescription sleep aids has also steered the patients towards OTC sleep aid. In 2016, the antihistamines sleep aids segment is expected to hold the largest share of the over-the-counter sleep aids market, whereas, melatonin is expected to grow at the highest CAGR during the forecast period. Growing awareness about the advantages of melatonin such as least amount of side effects, reduces stress levels, and its growing consumption is driving the growth of this segment in the U.S.

Some of the key players offering insomnia treatment (pharmacological) include Eisai, Co. Ltd. (Japan), Merck & Co., Inc. (U.S.), Meda Consumer Healthcare Inc. (U.S.), Pfizer, Inc. (U.S.), Sanofi (France), Takeda Pharmaceutical Company Ltd. (Japan), Pernix Therapeutics (U.S.), and Purdue Pharma L.P. (U.S.).

Research Coverage

The market study covers the U.S. insomnia market, by type of treatment, to estimate the overall market size during 2013 to 2021. This report also covers the drivers, restraints, and opportunities of the market along with the competitive landscape of the U.S. insomnia market players.

Reasons to buy this report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps firms to garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

* Market Penetration: Comprehensive information regarding products and services offered by the top players in the U.S. insomnia market
* Product Development/Innovation: Detailed insights on research & development activities, and new product launches in the U.S. insomnia market
* Market Diversification: Exhaustive information about new products, recent developments, and investments in the U.S. insomnia market
* Competitive Assessment: In-depth assessment of strategies, products, and pipeline products of the key players in the U.S. insomnia market

About MarketsandMarkets

MarketsandMarkets (M&M) is a global market research and consulting company based in the U.S. The company publishes high-level strategically analyzed reports for over ten industry verticals and serves as a business intelligence partner to Fortune 500 companies across the world. View more research from Markets and Markets at

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

Press Information

Published by
Bill Thompson

# 757 Words
Related Articles
More From The Author
"Polishes in Poland" is now available at [..]
A great variety of products that aim to meet specific customer needs, such as products for polishing furniture, floors, decorative [..]
New Market Report: United Kingdom Bone Densitometers [..]
GlobalData's new report, "United Kingdom Bone Densitometers Market Outlook to 2022", provides key market data on [..]
New market study, "Table Sauces in Chile [..]
Table Sauces in Chile by Mintel Market Sizes provides you with annual year-end market size data, most recently updated in [..]
Now Available: Leisure and Personal Goods Specialist [..]
Bags and Luggage Specialist Retailers: Bags and luggage specialist retailers failed to benefit from a good performance for bags [..]
New Report Available: Global Compression Therapy Market [..]
Compression is a technique for supporting the venous system in the preventive setting and acute and post thrombosis care. Therapeutic [..]
More From Health
Frost & Sullivan independent industry report identifies [..]
PERTH, W. AUSTRALIA, Mar 28, 2017 - (ACN Newswire) - Proteomics International Laboratories Ltd (PILL; ASX:PIQ) is the leader in [..]
New dynamics in monitoring diagnostics in leukemia
Dresden/Germany Diagnosis leukemia and stem cell transplantation The diagnosis "leukemia" for patients means to undergo [..]
PromarkerD Predictive Diagnostics for DKD to Roll-out [..]
PERTH, AUSTRALIA, Mar 22, 2017 - (ACN Newswire) - Proteomics International Laboratories Ltd ('PILL'; ASX: PIQ), a world leader [..]
Do Prostalgene Drops Help To Restore Prostate [..]
Prostate enlargement is among the most common health problems for men over 50. With age the incidence of this condition [..]
Is OnycoSolve Spray The Key To Obliterating [..]
Toenail fungus is an undesirable but stubborn infection that comes with sweating, itching, cracking and scaling of the feet, inflammations, [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.